Literature DB >> 16228054

Serosurvey of measles, mumps and rubella antibodies in Saudi children.

Yagob Y Al-Mazrou1, Mohamed K Khalil, Annedore Tischer, Mohamed H Al-Jeffri, Yasser S Al-Ghamdi, Mohamed M Bakhsh, Ameen A Mishkas, Sirag A Elgizouli.   

Abstract

OBJECTIVE: A serosurvey study to evaluate the proportion of children with antibodies against diseases targeted by the Expanded Program of Immunization in the Kingdom of Saudi Arabia.
METHODS: Using multistage sampling techniques, we collected samples and sent them for laboratory assay from the following age groups; 100 samples at 6 months, 12 months, 18 months, 6 years, 13 years, and 17 years. We conducted the study from September 2001 to February 2002. We assayed sera for measles, rubella, and mumps antibodies in the measles-mumps-rubella reference laboratory in Germany, using enzyme immunoassay and plaque neutralization (PN) as a backup test for equivocal and negative samples. We only carried out a backup test for measles samples.
RESULTS: The age group of 6 months had the highest proportion with negative measles antibodies. After adding the backup test (PN), the proportions of children with protective measles antibody were; 64% at 6 months, 87% at 12 months, 91% at 18 months, 75% at 6 years, 96% at 13 years, and 98% at 17 years. Rubella antibody positivity rates (>7 IU) were 28% at 6 months, 49% at 12 months, 97% at 18 months, 98% at 6 years, and 100% at 13 years. While positivity rates in mumps were 14% at 6 months, 29% at 12 months, 59% at 18 months, 64% at 6 years, and 75% at 13 years.
CONCLUSION: The unexpected low proportion of children with protective level at 6 years, despite being vaccinated with 2 measle doses is an important phenomenon. This reflects the interference between the first and the second measles dose. The Ministry of Health decided to conduct a catch up campaign targeting 1st through 3rd grade primary schools, who did not catch the mass campaign conducted in 2000. Also, this supports the decision taken by the ministry to change the measles immunization schedule to MMR at 12 months and a second dose at 6 years of age.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228054

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  3 in total

1.  Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.

Authors:  Manoj V Murhekar; Nivedita Gupta; Alvira Z Hasan; Muthusamy Santhosh Kumar; V Saravana Kumar; Christine Prosperi; Gajanan N Sapkal; Jeromie Wesley Vivian Thangaraj; Ojas Kaduskar; Vaishali Bhatt; Gururaj Rao Deshpande; Ullas Padinjaremattathil Thankappan; Avi Kumar Bansal; Sanjay L Chauhan; Gangandeep Singh Grover; Arun Kumar Jain; Ragini N Kulkarni; Santanu Kumar Sharma; Itta K Chaaithanya; Sanchit Kharwal; Sunil K Mishra; Neha R Salvi; Sandeep Sharma; Nilanju P Sarmah; R Sabarinathan; Augustine Duraiswamy; D Sudha Rani; K Kanagasabai; Abhishek Lachyan; Poonam Gawali; Mitali Kapoor; Arpit Kumar Shrivastava; Saurabh Kumar Chonker; Bipin Tilekar; Babasaheb V Tandale; Mohammad Ahmad; Lucky Sangal; Amy Winter; Sanjay M Mehendale; William J Moss; Kyla Hayford
Journal:  Lancet Glob Health       Date:  2022-11       Impact factor: 38.927

2.  A Nationwide Study on the Seroprevalence of Measles, Mumps, and Rubella in Iranian Children and Adolescents.

Authors:  Zary Nokhodian; Behrooz Ataei; Mohammad Mehdi Gouya; Shervin Ghaffari Hoseini; Majid Yaran; Marjan Mansourian; Mohammad Esmaeil Motlagh; Ramin Heshmat; Seyed Mohsen Zahraei; Roya Kelishadi
Journal:  Iran J Public Health       Date:  2022-02       Impact factor: 1.479

3.  Seroprevalence of measles antibodies and factors associated with susceptibility: a national survey in Mexico using a plaque reduction neutralization test.

Authors:  José Luis Díaz-Ortega; Elizabeth Ferreira-Guerrero; Luis Pablo Cruz-Hervert; Guadalupe Delgado-Sánchez; Leticia Ferreyra-Reyes; Mercedes Yanes-Lane; Norma Mongua-Rodríguez; Rogelio Montero-Campos; Deyanira Castañeda-Desales; Lourdes García-García
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.